KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling

KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling

Triple‐negative breast cancer (TNBC) is an aggressive breast cancer subtype, which has poor prognosis due to the lack of effective targeted drugs. KPT‐330, an inhibitor of the nuclear export protein CRM‐1, has been widely used in clinical medicine. Y219, a novel proteasome inhibitor designed by our...

Full description

Bibliographic Details
Main Authors: Tiantian Wen, Mengzhu Geng, Enhe Bai, Xueyuan Wang, Hang Miao, Zhimeng Chen, Hui Zhou, Jia Wang, Jingmiao Shi, Yin Zhang, Meng Lei, Yongqiang Zhu
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:FEBS Open Bio
Subjects:
KPT‐330
NF‐κB
triple‐negative breast cancer
Y219
Online Access:https://doi.org/10.1002/2211-5463.13588

Internet

https://doi.org/10.1002/2211-5463.13588

Similar Items